Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
J Cutan Pathol ; 48(5): 617-624, 2021 May.
Article in English | MEDLINE | ID: mdl-33415780

ABSTRACT

BACKGROUND: Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is associated with an increased risk of a second malignancy. METHODS: We conducted a retrospective clinicopathologic review of 12 patients with CLL/SLL who developed a second lymphoma in the skin. Demographic data, clinical information, and histopathology from 31 biopsies were recorded. Cases of secondary cutaneous involvement by CLL/SLL (leukemia cutis) and non-primary cutaneous lymphomas were excluded. RESULTS: A wide variety of primary cutaneous lymphomas was identified, including classic mycosis fungoides (3), cutaneous marginal zone lymphoma (2), primary cutaneous peripheral T-cell lymphoma unspecified (2), folliculotropic mycosis fungoides (1), Sézary syndrome (1), cutaneous gamma-delta T-cell lymphoma (1), cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma (1), and cutaneous anaplastic large cell lymphoma (1). A male predominance was observed, and the average age was 74.1 years. In all patients, CLL/SLL predated the development of the second lymphoma, which was aggressive in the majority of cases (58%). Aggressive cytotoxic T-cell lymphomas, generally rare neoplasms, were relatively common (30%). CONCLUSIONS: CLL/SLL patients may develop a second lymphoma in the skin, which may be aggressive. Atypical cutaneous lymphoid infiltrates in this patient population should not be assumed to represent secondary CLL/SLL involvement and require thorough immunohistochemical analysis.


Subject(s)
Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Lymphoma/diagnosis , Mycosis Fungoides/pathology , Skin Neoplasms/pathology , Aged , Aged, 80 and over , Biomarkers, Tumor/analysis , Biopsy , Female , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/complications , Lymphoma, B-Cell, Marginal Zone/complications , Lymphoma, B-Cell, Marginal Zone/pathology , Lymphoma, Large-Cell, Anaplastic/complications , Lymphoma, Large-Cell, Anaplastic/pathology , Lymphoma, T-Cell, Cutaneous/complications , Lymphoma, T-Cell, Cutaneous/pathology , Male , Middle Aged , Mycosis Fungoides/complications , Neoplasms, Second Primary/pathology , Retrospective Studies , Sezary Syndrome/complications , Sezary Syndrome/pathology , Skin Neoplasms/metabolism
2.
Mol Cancer Res ; 14(10): 1009-1018, 2016 10.
Article in English | MEDLINE | ID: mdl-27418645

ABSTRACT

Recently, we identified that PREX1 overexpression is critical for metastatic but not tumorigenic growth in a mouse model of NRAS-driven melanoma. In addition, a PREX1 gene signature correlated with and was dependent on ERK MAPK activation in human melanoma cell lines. In the current study, the underlying mechanism of PREX1 overexpression in human melanoma was assessed. PREX1 protein levels were increased in melanoma tumor tissues and cell lines compared with benign nevi and normal melanocytes, respectively. Suppression of PREX1 by siRNA impaired invasion but not proliferation in vitro PREX1-dependent invasion was attributable to PREX1-mediated activation of the small GTPase RAC1 but not the related small GTPase CDC42. Pharmacologic inhibition of ERK signaling reduced PREX1 gene transcription and additionally regulated PREX1 protein stability. This ERK-dependent upregulation of PREX1 in melanoma, due to both increased gene transcription and protein stability, contrasts with the mechanisms identified in breast and prostate cancers, in which PREX1 overexpression was driven by gene amplification and HDAC-mediated gene transcription, respectively. Thus, although PREX1 expression is aberrantly upregulated and regulates RAC1 activity and invasion in these three different tumor types, the mechanisms of its upregulation are distinct and context dependent. IMPLICATIONS: This study identifies an ERK-dependent mechanism that drives PREX1 upregulation and subsequent RAC1-dependent invasion in BRAF- and NRAS-mutant melanoma. Mol Cancer Res; 14(10); 1009-18. ©2016 AACR.


Subject(s)
GTP Phosphohydrolases/genetics , Guanine Nucleotide Exchange Factors/genetics , Guanine Nucleotide Exchange Factors/metabolism , Melanoma/genetics , Membrane Proteins/genetics , Mutation , Proto-Oncogene Proteins B-raf/genetics , Animals , Cell Line, Tumor , Cell Movement , Female , Gene Expression Regulation, Neoplastic , Humans , Indazoles/pharmacology , Indoles/pharmacology , MAP Kinase Signaling System , Male , Melanoma/metabolism , Mice , Piperazines/pharmacology , Pyridones/pharmacology , Pyrimidinones/pharmacology , Sulfonamides/pharmacology , Up-Regulation , Vemurafenib
3.
Nat Commun ; 2: 555, 2011 Nov 22.
Article in English | MEDLINE | ID: mdl-22109529

ABSTRACT

Metastases are the major cause of death from melanoma, a skin cancer that has the fastest rising incidence of any malignancy in the Western world. Molecular pathways that drive melanoblast migration in development are believed to underpin the movement and ultimately the metastasis of melanoma. Here we show that mice lacking P-Rex1, a Rac-specific Rho GTPase guanine nucleotide exchange factor, have a melanoblast migration defect during development evidenced by a white belly. Moreover, these P-Rex1(-/-) mice are resistant to metastasis when crossed to a murine model of melanoma. Mechanistically, this is associated with P-Rex1 driving invasion in a Rac-dependent manner. P-Rex1 is elevated in the majority of human melanoma cell lines and tumour tissue. We conclude that P-Rex1 has an important role in melanoblast migration and cancer progression to metastasis in mice and humans.


Subject(s)
Cell Movement/physiology , Guanine Nucleotide Exchange Factors/metabolism , Melanoma/metabolism , Melanoma/pathology , Neoplasm Metastasis/physiopathology , Animals , Cell Movement/genetics , Cells, Cultured , Guanine Nucleotide Exchange Factors/genetics , Humans , Immunohistochemistry , In Vitro Techniques , Melanoma/genetics , Mice , Mice, Inbred C57BL , Mice, Knockout , Neoplasm Metastasis/genetics , Tissue Array Analysis
4.
Ophthalmic Plast Reconstr Surg ; 25(4): 330-2, 2009.
Article in English | MEDLINE | ID: mdl-19617803

ABSTRACT

An 18-day-old child presented with rapid enlargement of a firm subcutaneous eyelid mass present since birth. Imaging revealed extension into the anterior orbit. Incisional biopsy revealed juvenile xanthogranuloma. Multidisciplinary systemic evaluation revealed no other lesions, although thrombocytopenia was discovered, prompting a bone marrow biopsy to rule out malignancy. Once none were uncovered, the thrombocytopenia was felt to be consistent with idiopathic thrombocytopenia. The patient was treated with intralesional steroid injections and concurrent oral prednisolone to normalize platelet count. The lesion softened, and reinjection 4 weeks later induced further regression, allowing the eyelid to clear the pupil. Although ocular involvement is a commonly reported extracutaneous manifestation of juvenile xanthogranuloma, a congenital subcutaneous eyelid lesion with orbital involvement has not been previously reported. Juvenile xanthogranuloma is typically benign and self-limiting; however, it can be associated with systemic disease, and treatment may be necessary to prevent amblyopia if the eyelid is involved. Early multidisciplinary evaluation for systemic lesions and associated malignant conditions should be considered.


Subject(s)
Eyelid Diseases/diagnosis , Eyelids/pathology , Xanthogranuloma, Juvenile/diagnosis , Administration, Oral , Biopsy , Dexamethasone/administration & dosage , Dexamethasone/therapeutic use , Diagnosis, Differential , Drug Therapy, Combination , Eyelid Diseases/drug therapy , Follow-Up Studies , Glucocorticoids/administration & dosage , Glucocorticoids/therapeutic use , Humans , Infant, Newborn , Injections , Magnetic Resonance Imaging , Prednisolone/administration & dosage , Prednisolone/therapeutic use , Triamcinolone/administration & dosage , Triamcinolone/therapeutic use , Xanthogranuloma, Juvenile/drug therapy
6.
Nat Neurosci ; 6(7): 717-23, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12796783

ABSTRACT

Agrin signals through the muscle-specific receptor tyrosine kinase (MuSK) to cluster acetylcholine receptors (AChRs) on the postsynaptic membrane of the neuromuscular junction (NMJ). This stands as the prevailing model of synapse induction by a presynaptic factor, yet the agrin-dependent MuSK signaling cascade is largely undefined. Abl1 (previously known as Abl) and the Abl1-related gene product Abl2 (previously known as Arg) define a family of tyrosine kinases that regulate actin structure and presynaptic axon guidance. Here we show that the Abl kinases are critical mediators of postsynaptic assembly downstream of agrin and MuSK. In mouse muscle, Abl kinases were localized to the postsynaptic membrane of the developing NMJ. In cultured myotubes, Abl kinase activity was required for agrin-induced AChR clustering and enhancement of MuSK tyrosine phosphorylation. Moreover, MuSK and Abl kinases effected reciprocal tyrosine phosphorylation and formed a complex after agrin engagement. Our findings suggest that Abl kinases provide the developing synapse with the kinase activity required for signal amplification and the intrinsic cytoskeletal regulatory capacity required for assembly and remodeling.


Subject(s)
Adaptor Proteins, Signal Transducing , Cytoskeletal Proteins , Homeodomain Proteins/metabolism , Neuromuscular Junction/physiology , Synapses/physiology , Agrin/physiology , Animals , Animals, Newborn/growth & development , Animals, Newborn/metabolism , Autonomic Denervation/methods , Benzamides , Blotting, Western/methods , Brain/metabolism , Bungarotoxins/metabolism , Cell Aggregation/drug effects , Cell Aggregation/physiology , Cells, Cultured , Dose-Response Relationship, Drug , Drug Interactions , Enzyme Inhibitors/pharmacology , Homeodomain Proteins/immunology , Imatinib Mesylate , Immunohistochemistry , In Vitro Techniques , Mice , Muscle Denervation/methods , Muscles/metabolism , Myoblasts/metabolism , Neurofilament Proteins/metabolism , Phosphorylation , Piperazines/pharmacology , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-crk , Pyrimidines/pharmacology , Rabbits , Radioimmunoassay , Receptor Protein-Tyrosine Kinases/metabolism , Receptors, Cholinergic/metabolism , Synaptophysin/metabolism , Time Factors , Transfection/methods , Tyrosine/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...